JAAOS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Am Acad Orthop Surg, Vol 10, No 2, March/April 2002, 138-151.
© 2002 the American Academy of Orthopaedic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sussman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sussman, M.

Duchenne Muscular Dystrophy

Michael Sussman, MD

Dr. Sussman is Staff Orthopedic Surgeon and Former Chief of Staff, Shriners Hospitals for Children, Portland, OR.

Reprint requests: Dr. Sussman, Shriners Hospitals for Children, 3101 SW Sam Jackson Park Road, Portland, OR 97201.

Duchenne muscular dystrophy is an X-linked disease of muscle caused by an absence of the protein dystrophin. Affected boys begin manifesting signs of disease early in life, cease walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, surgical, and rehabilitative approaches can be used to maintain patient function and comfort. Corticosteroids, including prednisone and a related compound, deflazacort, have recently been shown to markedly delay the loss of muscle strength and function in boys with Duchenne muscular dystrophy. Surgical release of lower extremity contractures may benefit some patients. Approximately 90% of boys with Duchenne muscular dystrophy will develop severe scoliosis, which is not amenable to control by nonsurgical means such as bracing or adaptive seating. The most effective treatment for severe scoliosis is prevention by intervening with early spinal fusion utilizing segmental instrumentation as soon as curves are ascertained and before the onset of severe pulmonary or cardiac dysfunction.




This article has been cited by other articles:


Home page
 NeurologyHome page
W. M. King, R. Ruttencutter, H. N. Nagaraja, V. Matkovic, J. Landoll, C. Hoyle, J. R. Mendell, and J. T. Kissel
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
Neurology, May 8, 2007; 68(19): 1607 - 1613.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
L. A. Karol
Scoliosis in Patients with Duchenne Muscular Dystrophy
J. Bone Joint Surg. Am., February 1, 2007; 89(suppl_1): 155 - 162.
[Full Text] [PDF]

Home page
 NeurologyHome page
R. T. Moxley III, S. Ashwal, S. Pandya, A. Connolly, J. Florence, K. Mathews, L. Baumbach, C. McDonald, M. Sussman, and C. Wade
Practice Parameter: Corticosteroid treatment of Duchenne dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society
Neurology, January 11, 2005; 64(1): 13 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S Jog, S Patole, and J Whitehall
Congenital scoliosis in a neonate: can a neonatologist ignore it?
Postgrad. Med. J., August 1, 2002; 78(922): 469 - 472.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Academy of Orthopaedic Surgeons.